<DOC>
	<DOC>NCT00284258</DOC>
	<brief_summary>This study is designed as Phase II/III. Phase II is aimed to evaluate safety and efficacy of IRIS, and feasibility of FOLFIRI. Phase III is aimed to verify inferiority of the progression free survival of IRIS in comparison with FOLFIRI.</brief_summary>
	<brief_title>Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically confirmed colorectal cancer Locally advanced and/or metastatic colorectal cancer Have prior chemotherapy as first line treatment No prior irinotecan administration Able to take oral medication Age 20 to 75 Performance status 0 or 1 (ECOG) WBC 3,00012,000 / mm^3 Platelet ≥100,000 / mm^3 AST and ALT ≤ 100 IU/L Creatinine ≤ 1.2 mg/dL Bilirubin ≤ 1.5 mg/dL Prior radio therapy for colorectal cancer Other malignancies in the past 5 years Serious illness or medical condition</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Colorectal Cancer</keyword>
</DOC>